FDA Deliberates on an Emerging Type 2 Diabetes Drug Class

With the PDUFA date for Johnson & Johnson's (NYSE: JNJ  ) SGLT-2 inhibitor Invokana just around the corner, the FDA will soon deliberate on another Type 2 diabetes drug that belongs to the same class: Eli Lilly's (NYSE: LLY  ) empagliflozin. Can these drugs get the green light, or will the FDA require both companies to run more clinical trials? Is the FDA's rejection of Forxiga, an SGLT-2 inhibitor developed by Bristol-Myers Squibb  (NYSE: BMY  ) and AstraZeneca (NYSE: AZN  ) a signal that these drugs will face an uphill battle during the approval process? Health-care analyst Max Macaluso discusses these topics in the following video.

Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more, click here to claim your copy today.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

DocumentId: 2330949, ~/Articles/ArticleHandler.aspx, 8/2/2014 4:50:36 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement